Alx oncology receives orphan drug designation from the european commission for evorpacept for the treatment of patients with gastric cancer

South san francisco, calif., june 26, 2023 (globe newswire) -- alx oncology holdings inc., (“alx oncology”) (nasdaq: alxo), a clinical-stage immuno-oncology company developing therapies that block the cd47 checkpoint pathway, today announced that evorpacept, a next-generation cd47 blocker, has received orphan drug designation (“odd”) from the european commission (“ec”) for the treatment of patients with gastric cancer. this odd indication includes both gastric cancer and gastroesophageal junction adenocarcinoma (collectively “gc”). the u.s. food and drug administration (“fda”) also granted odd to evorpacept for the treatment of patients with gc as previously announced in january 2022.
ALXO Ratings Summary
ALXO Quant Ranking